BioLASCO Taiwan Balance Sheet Health
Financial Health criteria checks 5/6
BioLASCO Taiwan has a total shareholder equity of NT$443.6M and total debt of NT$107.7M, which brings its debt-to-equity ratio to 24.3%. Its total assets and total liabilities are NT$581.3M and NT$137.7M respectively. BioLASCO Taiwan's EBIT is NT$50.2M making its interest coverage ratio -188.2. It has cash and short-term investments of NT$139.0M.
Key information
24.3%
Debt to equity ratio
NT$107.68m
Debt
| Interest coverage ratio | -188.2x |
| Cash | NT$139.02m |
| Equity | NT$443.64m |
| Total liabilities | NT$137.66m |
| Total assets | NT$581.30m |
Recent financial health updates
Recent updates
We Think You Should Be Aware Of Some Concerning Factors In BioLASCO Taiwan's (GTSM:6662) Earnings
Apr 01
Are BioLASCO Taiwan Co., Ltd.'s (GTSM:6662) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Mar 11Investors In BioLASCO Taiwan Co., Ltd. (GTSM:6662) Should Consider This, First
Feb 10
Is BioLASCO Taiwan (GTSM:6662) A Risky Investment?
Jan 08BioLASCO Taiwan Co., Ltd.'s (GTSM:6662) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
Dec 10Financial Position Analysis
Short Term Liabilities: 6662's short term assets (NT$207.6M) exceed its short term liabilities (NT$39.1M).
Long Term Liabilities: 6662's short term assets (NT$207.6M) exceed its long term liabilities (NT$98.6M).
Debt to Equity History and Analysis
Debt Level: 6662 has more cash than its total debt.
Reducing Debt: 6662's debt to equity ratio has increased from 2.1% to 24.3% over the past 5 years.
Debt Coverage: 6662's debt is well covered by operating cash flow (43.3%).
Interest Coverage: 6662 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 13:11 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioLASCO Taiwan Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|